Immunotherapy for metastatic renal-cell carcinoma in Germany: A nationwide survey;Immuntherapie des metastasierten nierenzellkarzinoms in Deutschland: Eine standortbestimmung

Urologe - Ausgabe A

Volumn 41, Issue 3, 2002, Pages 282-287

  Huland, Edith ^a   Heinzer, H ^a   Timm, S ^a   Aalamian, M ^a   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Interferon alpha; Interleukin 2; Metastatic renal cell carcinoma; Off label use

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; GERMANY; HEALTH SURVEY; HUMAN; KIDNEY CARCINOMA; LOCAL THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; SIDE EFFECT; SYSTEMIC THERAPY; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 0038009220     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-001-0170-2     Document Type: Article

References (11)

1. Atkins CD (1998) Ethics of off-label treatment. J Clin Oncol 16: 1637
2. Brosgart CL, Mitchell T, Charlebois E, Coleman R, Mehalko S, Young J, Abrams DI (1996) Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 12: 56-62
3. Cohen PJ (1997) "Off-label" use of prescription drugs: legal, clinical and policy considerations. Eur J Anaesthesiol 14: 231-235
4. Conroy S, Choonara I, Impicciatore P et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320: 79-82
5. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T (2000) Immunotherapy for advanced renal cell cancer (Cochrane review). Cochrane Database Syst Rev 3
6. FDA (1982) Drug Bulletin 12(4)
7. Fischer C (2001) Immuntherapie des Nierenzellkarzinoms: Schlusswort. Dtsch Ärztebl 13: B 723-724
8. Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17: 3612-3620
9. Henry V (1999) Off-label prescribing. Legal implications. J Leg Med 20: 365-383
10. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg W J, Metz E M (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18: 1928-1935
11. Schmoll HJ, Höffgen K, Possinger K (Hrsg) (1999) Kompendium Internistische Onkologie. Standard in Diagnostik und Therapie, 3. Aufl. Springer, Berlin Heidelberg New York Tokio, S173-215